ABSTRACT
Comments on an article by Valerie F. Reyna et al. (see record 2022-15515-001). Reyna and colleagues often argue that the processing of gist tends to be both fast and unconscious (the hallmarks of cognitive autonomy), whereas the processing of verbatim traces is slower and conscious. Their argument about the speed of processing dovetails with the assumption that gist representations are often simple and that reasoners are assumed to use the simplest gist available to them. Given a reasonable ancillary assumption that the processes that act on gist traces are simpler than those that act on verbatim ones, the primary assumption about the relative speed of gist and verbatim processes seems justified. The assumptions made about processing gist and verbatim traces are closely analogous to the DPT assumption about the relative speed of autonomous and WM-dependent reasoning: Like Type 1 processing, gist-based processing tends to be faster and is thus likely to be completed faster than the slower and more deliberate verbatim processing. There is a potentially fruitful alignment of the assumption made by FTT and DPT. The argument is grounded in the principle that theories of representation and processing are incomplete without each other. (PsycInfo Database Record (c) 2022 APA, all rights reserved)
ABSTRACT
Passive immunization using monoclonal antibodies will play a vital role in the fight against COVID-19. The recent emergence of viral variants with reduced sensitivity to some current antibodies and vaccines highlights the importance of broad cross-reactivity. This study describes deep-mining of the antibody repertoires of hospitalized COVID-19 patients using phage display technology and B cell receptor (BCR) repertoire sequencing to isolate neutralizing antibodies and gain insights into the early antibody response. This comprehensive discovery approach has yielded a panel of potent neutralizing antibodies which bind distinct viral epitopes including epitopes conserved in SARS-CoV-1. Structural determination of a non-ACE2 receptor blocking antibody reveals a previously undescribed binding epitope, which is unlikely to be affected by the mutations in any of the recently reported major viral variants including B.1.1.7 (from the UK), B.1.351 (from South Africa) and B.1.1.28 (from Brazil). Finally, by combining sequences of the RBD binding and neutralizing antibodies with the B cell receptor repertoire sequencing, we also describe a highly convergent early antibody response. Similar IgM-derived sequences occur within this study group and also within patient responses described by multiple independent studies published previously.